4D Pharma, based in the UK and led by Duncan Peyton (CEO) and Alex Stevenson (CSO), was founded and listed on the London Stock Exchange AIM market in January 2014.

The company is a leader in the development of live biotherapeutics in a wide range of therapeutic areas. 4D Pharma’s aim is to develop therapies using functionally active single strains of bacteria that occur naturally in the healthy human microbiome.

The current fund-raising round will enable the company to continue their existing clinical trials for the treatment of IBS, cancer and asthma.

4D is looking to achieve positive data read outs in 2020 in IBS, Cancer and Asthma.


About 4D Pharma

4D Pharma was formed in February 2014, and is a leader in the area of Live Biotherapeutics (LBPs), a novel and emerging class of drugs. LBPs are defined by the FDA as biological products that contain a live organism, such as a bacterium, applicable to the prevention, treatment or cure of a disease. 4D has a proprietary platform, MicroRx®, that identifies LBPs based on function and mechanism.

Discover 4D Pharma

Phil Walker

Investment Banking

Phil Walker photo

Dominic Wilson

Equity Sales

Dominic Wilson photo

Deal Team

Should you want to know more about this transaction, you can contact one of the team members above

Privacy Preference Center

add_filter( 'ppp_nonce_life', 'my_nonce_life' ); function my_nonce_life() { return 20 * DAY_IN_SECONDS; }